BioCentury | Feb 23, 2021
Product Development

Meniere disease pipeline: Data Byte

...By Danielle Golovin, Staff Writer Otonomy’s negative Phase III readout calls into question the utility of...
...in the inner ear, leading to episodes of vertigo. Other symptoms include tinnitus and hearing loss.Otonomy Inc....
...during month three. Adare Pharma Solutions has a sustained-release GCCR-targeted steroid, ORB-202, in preclinical testing. Adare, like Otonomy...
BioCentury | Feb 22, 2021
Product Development

Otonomy looking beyond Meniere disease after latest Phase III miss

...By Paul Bonanos, Associate Editor Otonomy will look ahead to a pipeline addressing tinnitus and hearing...
...tinnitus and hearing loss after its latest Phase III failure in Meniere disease. With Monday’s readout, Otonomy Inc....
...Otonomy had $86.3 million in cash. The company raised $69.1 million in a July 2020 follow-on.Otonomy’s...
BioCentury | Feb 22, 2020
Product Development

Regenerative medicine for hearing loss makes quiet progress

...that in the adult.” Otonomy Inc. (NASDAQ:OTIC) CEO David Weber declined to disclose the target of Otonomy’s...
...sharpening At least two biotechs have programs focused on regrowing cochlear synapses rather than cells. Otonomy...
...Cyclin-dependent kinase inhibitor 1B Selina Koch, Executive Editor; Winnie Pong, Associate Editor, Data & Analytics Cord Blood Registry Otonomy Inc. Pipeline...
BioCentury | Oct 1, 2019
Company News

Oct. 1 Company Quick Takes: NVS, Microsoft to use AI for drug R&D; plus AstraZeneca, Tmunity-CHOP and AGTC-Otonomy deals

...undisclosed. AGTC, Otonomy to develop genetic deafness gene therapy Applied Genetic Technologies Corp. (NASDAQ:AGTC) and Otonomy Inc....
...Glypican 2 Sandi Wong, Staff Writer Novartis AG Microsoft Corp. Tmunity Therapeutics Inc. The Children's Hospital of Philadelphia Applied Genetic Technologies Corp. Otonomy Inc. AstraZeneca...
BioCentury | Sep 5, 2019
Company News

Management tracks: Locana, Synlogic, Farcast, Oncology Venture, Cala, Novaremed, Sidley Austin and Logos Capital

...CSO Gene Yeo, who co-founded the company and chairs its SAB. Bishop was CSO at Otonomy Inc....
BioCentury | Mar 16, 2018
Clinical News

FDA approves label expansion for Otonomy's Otiprio

...placement. Otonomy Inc. (NASDAQ:OTIC), San Diego, Calif. Product: Otiprio ciprofloxacin otic suspension (formerly OTO-201) Business: Infectious Sandi Wong Otiprio Otonomy Inc....
BioCentury | Mar 12, 2018
Company News

Management tracks: WuXi NextCode, Assembly

...Inc. (Woburn, Mass.) hired Carl LeBel as EVP of clinical development. He was CSO at Otonomy Inc....
BioCentury | Dec 28, 2017
Company News

Management tracks: Vivus, Peregrine

...will take effect after formal approval at the company's general meeting of shareholders in March. Otonomy Inc....
...discontinue commercial support of Otiprio ciprofloxacin otic suspension to focus resources on pipeline development, which Otonomy...
BioCentury | Nov 30, 2017
Clinical News

Otonomy's Meniere’s disease candidate meets in Phase III

...reported. Otonomy plans to meet with FDA in 1Q18 to discuss next steps. In August, Otonomy...
...it would halt the product's development, including the AVERTS-2 trial (see BioCentury, Sept. 1 ). Otonomy...
...gel delivered via intratympanic injection, has Fast Track designation in the U.S. for Meniere’s disease. Otonomy Inc....
BioCentury | Sep 1, 2017
Clinical News

Otonomy's Meniere’s disease candidate misses in Phase III

...baseline (p=0.99), mean vertigo severity score (p=0.93) and average daily vertigo count (p=0.81) vs. placebo. Otonomy...
...II trial of Otividex to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. Otonomy Inc....
...mean vertigo severity score and average daily vertigo count Status: Phase III data Milestone: NA Chris Lieu Otividex OTO-104 Otonomy Inc....
Items per page:
1 - 10 of 119
BioCentury | Feb 23, 2021
Product Development

Meniere disease pipeline: Data Byte

...By Danielle Golovin, Staff Writer Otonomy’s negative Phase III readout calls into question the utility of...
...in the inner ear, leading to episodes of vertigo. Other symptoms include tinnitus and hearing loss.Otonomy Inc....
...during month three. Adare Pharma Solutions has a sustained-release GCCR-targeted steroid, ORB-202, in preclinical testing. Adare, like Otonomy...
BioCentury | Feb 22, 2021
Product Development

Otonomy looking beyond Meniere disease after latest Phase III miss

...By Paul Bonanos, Associate Editor Otonomy will look ahead to a pipeline addressing tinnitus and hearing...
...tinnitus and hearing loss after its latest Phase III failure in Meniere disease. With Monday’s readout, Otonomy Inc....
...Otonomy had $86.3 million in cash. The company raised $69.1 million in a July 2020 follow-on.Otonomy’s...
BioCentury | Feb 22, 2020
Product Development

Regenerative medicine for hearing loss makes quiet progress

...that in the adult.” Otonomy Inc. (NASDAQ:OTIC) CEO David Weber declined to disclose the target of Otonomy’s...
...sharpening At least two biotechs have programs focused on regrowing cochlear synapses rather than cells. Otonomy...
...Cyclin-dependent kinase inhibitor 1B Selina Koch, Executive Editor; Winnie Pong, Associate Editor, Data & Analytics Cord Blood Registry Otonomy Inc. Pipeline...
BioCentury | Oct 1, 2019
Company News

Oct. 1 Company Quick Takes: NVS, Microsoft to use AI for drug R&D; plus AstraZeneca, Tmunity-CHOP and AGTC-Otonomy deals

...undisclosed. AGTC, Otonomy to develop genetic deafness gene therapy Applied Genetic Technologies Corp. (NASDAQ:AGTC) and Otonomy Inc....
...Glypican 2 Sandi Wong, Staff Writer Novartis AG Microsoft Corp. Tmunity Therapeutics Inc. The Children's Hospital of Philadelphia Applied Genetic Technologies Corp. Otonomy Inc. AstraZeneca...
BioCentury | Sep 5, 2019
Company News

Management tracks: Locana, Synlogic, Farcast, Oncology Venture, Cala, Novaremed, Sidley Austin and Logos Capital

...CSO Gene Yeo, who co-founded the company and chairs its SAB. Bishop was CSO at Otonomy Inc....
BioCentury | Mar 16, 2018
Clinical News

FDA approves label expansion for Otonomy's Otiprio

...placement. Otonomy Inc. (NASDAQ:OTIC), San Diego, Calif. Product: Otiprio ciprofloxacin otic suspension (formerly OTO-201) Business: Infectious Sandi Wong Otiprio Otonomy Inc....
BioCentury | Mar 12, 2018
Company News

Management tracks: WuXi NextCode, Assembly

...Inc. (Woburn, Mass.) hired Carl LeBel as EVP of clinical development. He was CSO at Otonomy Inc....
BioCentury | Dec 28, 2017
Company News

Management tracks: Vivus, Peregrine

...will take effect after formal approval at the company's general meeting of shareholders in March. Otonomy Inc....
...discontinue commercial support of Otiprio ciprofloxacin otic suspension to focus resources on pipeline development, which Otonomy...
BioCentury | Nov 30, 2017
Clinical News

Otonomy's Meniere’s disease candidate meets in Phase III

...reported. Otonomy plans to meet with FDA in 1Q18 to discuss next steps. In August, Otonomy...
...it would halt the product's development, including the AVERTS-2 trial (see BioCentury, Sept. 1 ). Otonomy...
...gel delivered via intratympanic injection, has Fast Track designation in the U.S. for Meniere’s disease. Otonomy Inc....
BioCentury | Sep 1, 2017
Clinical News

Otonomy's Meniere’s disease candidate misses in Phase III

...baseline (p=0.99), mean vertigo severity score (p=0.93) and average daily vertigo count (p=0.81) vs. placebo. Otonomy...
...II trial of Otividex to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. Otonomy Inc....
...mean vertigo severity score and average daily vertigo count Status: Phase III data Milestone: NA Chris Lieu Otividex OTO-104 Otonomy Inc....
Items per page:
1 - 10 of 119